Frontiers in Oncology | Thoracic Oncology

Systematic Review

Published on 11 Jan 2021

Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials

in Thoracic Oncology

Xiang Li
Shi Yan
Jichun Yang
Yaqi Wang
Chao Lv
Shaolei Li
Jun Zhao
Yue Yang
Minglei Zhuo
Nan Wu

Frontiers in Oncology

doi 10.3389/fonc.2020.574752

8,258 views
19 citations

Original Research

Published on 08 Jan 2021

Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort

in Thoracic Oncology

Sheng-Kai Liang
Li-Ta Keng
Chia-Hao Chang
Yueh-Feng Wen
Meng-Rui Lee
Ching-Yao Yang
Jann-Yuan Wang
Jen-Chung Ko
Jin-Yuan Shih
Chong-Jen Yu

Frontiers in Oncology

doi 10.3389/fonc.2020.590356

4,823 views
7 citations

Original Research

Published on 08 Jan 2021

MYBL2-Driven Transcriptional Programs Link Replication Stress and Error-prone DNA Repair With Genomic Instability in Lung Adenocarcinoma

in Thoracic Oncology

Benjamin B. Morris
Nolan A. Wages
Patrick A. Grant
P. Todd Stukenberg
Ryan D. Gentzler
Richard D. Hall
Wallace L. Akerley
Thomas K. Varghese
Susanne M. Arnold
Terence M. Williams

Frontiers in Oncology

doi 10.3389/fonc.2020.585551

9,097 views
15 citations

Original Research

Published on 06 Jan 2021

Changes of Brain Structure in Patients With Metastatic Non-Small Cell Lung Cancer After Long-Term Target Therapy With EGFR-TKI

in Thoracic Oncology

Beisheng Yang
Chunli Luo
Min Yu
Lin Zhou
Bo Tao
Biqiu Tang
Ying Zhou
Jiang Zhu
Meijuan Huang
Feng Peng

Frontiers in Oncology

doi 10.3389/fonc.2020.573512

6,780 views
4 citations

Original Research

Published on 23 Dec 2020

Relevance of STK11 Mutations Regarding Immune Cell Infiltration, Drug Sensitivity, and Cellular Processes in Lung Adenocarcinoma

in Thoracic Oncology

Zhenqing Li
Bo Ding
Jianxun Xu
Kai Mao
Pengfei Zhang
Qun Xue

Frontiers in Oncology

doi 10.3389/fonc.2020.580027

6,592 views
15 citations

Original Research

Published on 23 Dec 2020

Dyspnea in Patients Receiving Radical Radiotherapy for Non-Small Cell Lung Cancer: A Prospective Study

in Thoracic Oncology

Angela Sardaro
Fiona McDonald
Lilia Bardoscia
Konstantin Lavrenkov
Shalini Singh
Sue Ashley
Daphne Traish
Cristina Ferrari
Icro Meattini
Artor Niccoli Asabella

Frontiers in Oncology

doi 10.3389/fonc.2020.594590

4,286 views
8 citations

Original Research

Published on 22 Dec 2020

Thymic Squamous Cell Carcinoma: A Population-Based Surveillance, Epidemiology, and End Result Analysis

in Thoracic Oncology

Xudong Yang
Kejia Zhao
Chuan Li
Yanbo Yang
Chenglin Guo
Yi Pu
Lunxu Liu

Frontiers in Oncology

doi 10.3389/fonc.2020.592023

10,370 views
17 citations

Original Research

Published on 21 Dec 2020

Alpha Thalassemia/Intellectual Disability X-Linked Deficiency Sensitizes Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors

in Thoracic Oncology

Tao Hou
Shun Jiang
Yapeng Wang
Yangchun Xie
Haixia Zhang
Yeqian Feng
Fang Ma
Jin’an Ma
Xianling Liu
Chunhong Hu

Frontiers in Oncology

doi 10.3389/fonc.2020.608300

5,014 views
15 citations

Review

Published on 18 Dec 2020

Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors

in Thoracic Oncology

Leilei Wu
Linping Ke
Zhenshan Zhang
Jinming Yu
Xue Meng

Frontiers in Oncology

doi 10.3389/fonc.2020.602762

43,268 views
92 citations

Case Report

Published on 17 Dec 2020

Lung Adenocarcinoma Harboring EGFR Kinase Domain Duplication (EGFR-KDD) Confers Sensitivity to Osimertinib and Nivolumab: A Case Report

in Thoracic Oncology

Jie Li
Junrong Yan
Ran Cao
Guanjun Du
Guofang Zhao

Frontiers in Oncology

doi 10.3389/fonc.2020.575739

4,704 views
6 citations

Original Research

Published on 16 Dec 2020

Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer

in Thoracic Oncology

Federico Cucchiara
Marzia Del Re
Simona Valleggi
Chiara Romei
Iacopo Petrini
Maurizio Lucchesi
Stefania Crucitta
Eleonora Rofi
Annalisa De Liperi
Antonio Chella

Frontiers in Oncology

doi 10.3389/fonc.2020.593831

8,202 views
39 citations

Original Research

Published on 15 Dec 2020

Genotyping Squamous Cell Lung Carcinoma in Colombia (Geno1.1-CLICaP)

in Thoracic Oncology

Andrés F. Cardona
Alejandro Ruiz-Patiño
Oscar Arrieta
Luisa Ricaurte
Zyanya Lucia Zatarain-Barrón
July Rodriguez
Jenny Avila
Leonardo Rojas
Gonzalo Recondo
Feliciano Barron

Frontiers in Oncology

doi 10.3389/fonc.2020.588932

4,647 views
7 citations

Original Research

Published on 15 Dec 2020

Value of N1 Lymph Node Examination in the Prognosis of Patients With pT1-3N0M0 Non-Small Cell Lung Cancer

in Thoracic Oncology

Gaoxiang Wang
Xianning Wu
Xiaohui Sun
Tian Li
Meiqing Xu
Liangdong Xu
Mingran Xie

Frontiers in Oncology

doi 10.3389/fonc.2020.603378

2,841 views
6 citations

Original Research

Published on 14 Dec 2020

Performance Evaluation of SHOX2 and RASSF1A Methylation for the Aid in Diagnosis of Lung Cancer Based on the Analysis of FFPE Specimen

in Thoracic Oncology

Juanhong Shi
Xue Chen
Long Zhang
Xia Fang
Yuting Liu
Xuyou Zhu
Haoyang Zhang
Lichao Fan
Jun Gu
Suxia Zhang

Frontiers in Oncology

doi 10.3389/fonc.2020.565780

5,830 views
27 citations

Review

Published on 14 Dec 2020

Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors–Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment

in Thoracic Oncology

Yoshie Yoshikawa
Kozo Kuribayashi
Toshiyuki Minami
Masaki Ohmuraya
Takashi Kijima

Frontiers in Oncology

doi 10.3389/fonc.2020.554570

7,230 views
22 citations

Original Research

Published on 11 Dec 2020

Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer

in Thoracic Oncology

Jin Kang
Xu-Chao Zhang
Hua-Jun Chen
Wen-Zhao Zhong
Yang Xu
Jian Su
Qing Zhou
Hai-Yan Tu
Zhen Wang
Chong-Rui Xu

Frontiers in Oncology

doi 10.3389/fonc.2020.596937

9,930 views
35 citations

Review

Published on 10 Dec 2020

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

in Thoracic Oncology

Yijia Guo
Jun Song
Yanru Wang
Letian Huang
Li Sun
Jianzhu Zhao
Shuling Zhang
Wei Jing
Jietao Ma
Chengbo Han

Frontiers in Oncology

doi 10.3389/fonc.2020.610923

20,052 views
89 citations

Original Research

Published on 10 Dec 2020

Comprehensive Molecular Characterizations of Chinese Patients With Different Subtypes of Lung Squamous Cell Carcinoma

in Thoracic Oncology

Jie Qian
Rongrong Chen
Ruiying Zhao
Yuchen Han
Yongfeng Yu

Frontiers in Oncology

doi 10.3389/fonc.2020.607130

4,385 views
9 citations

Original Research

Published on 09 Dec 2020

Microbiome Related Cytotoxically Active CD8+ TIL Are Inversely Associated With Lung Cancer Development

in Thoracic Oncology

Leliang Zheng
Jiaqi Xu
Buqing Sai
Yinghong Zhu
Lujuan Wang
Na Yin
Fenglei Yu
Wen Zhou
Minghua Wu
Jingqun Tang

Frontiers in Oncology

doi 10.3389/fonc.2020.531131

5,497 views
23 citations

Original Research

Published on 09 Dec 2020

Monoacylglycerol Lipase Knockdown Inhibits Cell Proliferation and Metastasis in Lung Adenocarcinoma

in Thoracic Oncology

Hao Zhang
Wei Guo
Fan Zhang
Renda Li
Yang Zhou
Fei Shao
Xiaoli Feng
Fengwei Tan
Jie Wang
Shugeng Gao

Frontiers in Oncology

doi 10.3389/fonc.2020.559568

6,209 views
22 citations

Original Research

Published on 08 Dec 2020

Combination of Serum Amyloid A and C-Reactive Protein Exhibit Synergistic Effect in Angiogenesis by Inducing Inflammation and Vascular Network

in Thoracic Oncology

Dan Liu
Yonghe Chen
Yunxiu Wang
Mangjuan Lei
Lin Chen
Rongliang Liang
Zhaomin Cheng
Wen Shi
Huimin Wang
Li Lin

Frontiers in Oncology

doi 10.3389/fonc.2020.576207

4,417 views
6 citations

Original Research

Published on 07 Dec 2020

Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer

in Thoracic Oncology

Shuai Yuan
Ying Xiang
Xiaoping Guo
Yao Zhang
Chengying Li
Weijia Xie
Na Wu
Long Wu
Tongjian Cai
Xiangyu Ma

Frontiers in Oncology

doi 10.3389/fonc.2020.537120

5,994 views
29 citations

Original Research

Published on 04 Dec 2020

First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis

in Thoracic Oncology

Longfeng Zhang
Yongfu Hang
Maobai Liu
Na Li
Hongfu Cai

Frontiers in Oncology

doi 10.3389/fonc.2020.602185

7,302 views
32 citations

Mini Review

Published on 04 Dec 2020

The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors

in Thoracic Oncology

Marcin Nicoś
Paweł Krawczyk
Nicola Crosetto
Janusz Milanowski

Frontiers in Oncology

doi 10.3389/fonc.2020.569202

6,048 views
33 citations

1,976 articles

articles

Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials

Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort

MYBL2-Driven Transcriptional Programs Link Replication Stress and Error-prone DNA Repair With Genomic Instability in Lung Adenocarcinoma

Changes of Brain Structure in Patients With Metastatic Non-Small Cell Lung Cancer After Long-Term Target Therapy With EGFR-TKI

Relevance of STK11 Mutations Regarding Immune Cell Infiltration, Drug Sensitivity, and Cellular Processes in Lung Adenocarcinoma

Dyspnea in Patients Receiving Radical Radiotherapy for Non-Small Cell Lung Cancer: A Prospective Study

Thymic Squamous Cell Carcinoma: A Population-Based Surveillance, Epidemiology, and End Result Analysis

Alpha Thalassemia/Intellectual Disability X-Linked Deficiency Sensitizes Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors

Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors

Lung Adenocarcinoma Harboring EGFR Kinase Domain Duplication (EGFR-KDD) Confers Sensitivity to Osimertinib and Nivolumab: A Case Report

Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer

Genotyping Squamous Cell Lung Carcinoma in Colombia (Geno1.1-CLICaP)

Value of N1 Lymph Node Examination in the Prognosis of Patients With pT1-3N0M0 Non-Small Cell Lung Cancer

Performance Evaluation of SHOX2 and RASSF1A Methylation for the Aid in Diagnosis of Lung Cancer Based on the Analysis of FFPE Specimen

Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors–Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment

Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

Comprehensive Molecular Characterizations of Chinese Patients With Different Subtypes of Lung Squamous Cell Carcinoma

Microbiome Related Cytotoxically Active CD8+ TIL Are Inversely Associated With Lung Cancer Development

Monoacylglycerol Lipase Knockdown Inhibits Cell Proliferation and Metastasis in Lung Adenocarcinoma

Combination of Serum Amyloid A and C-Reactive Protein Exhibit Synergistic Effect in Angiogenesis by Inducing Inflammation and Vascular Network

Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer

First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis

The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors